MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life

  • Clinical trial will evaluate the effectiveness of MediPharm Labs proprietary GMP cannabis-derived formulations and medical products and expand MediPharm Labs owned IP
  • In the United States, 37 million or more than 1 in 7 adults, are estimated to have chronic kidney disease (CKD) and Worldwide, approximately 1 in 10 people suffer from kidney disease according to the National Kidney Foundation
  • Patients with CKD suffer from various symptoms and have limited life expectancy, consequently, optimizing quality of life (QOL) is of high priority

/EIN News/ — BARRIE, Ontario, Oct. 19, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its…

Original Author Link click here to read complete story..

Latest posts